CRISPR Therapeutics granted FDA RMAT for CTX110 for CD19+ B-cell cancers

By The Science Advisory Board staff writers

November 29, 2021 -- CRISPR Therapeutics received the U.S. Food and Drug Administration (FDA) regenerative medicine advanced therapy (RMAT) designation for CTX110, an allogeneic CAR T-cell therapy, for the treatment of relapsed or refractory CD19+ B-cell malignancies.

CTX110 is a donor-derived, gene-edited, allogeneic CAR T investigational therapy that targets B-lymphocyte antigen CD19. It is the subject of the ongoing CARBON clinical trial, a phase I, single-arm, multicenter, open-label clinical trial designed to assess safety and efficacy, according to the company.

The RMAT designation expedites the drug development and review processes for promising cell therapies that are intended to treat, modify, reverse, or cure a serious or life-threatening disease or condition that has unmet medical or therapeutic need. Similar to the FDA's Breakthrough Therapy designation, the RMAT designation provides the benefits of intensive FDA guidance on efficient drug development, potential accelerated approval and post-approval requirements, as well as potential priority review of the biologics license application.

CRISPR Therapeutics develops genetically engineered therapies for serious diseases in the fields of hemoglobinopathies, oncology, regenerative medicine, and rare diseases, using its proprietary CRISPR-Cas9 gene-editing platform. CRISPR Therapeutics has partnerships with Bayer, Vertex Pharmaceuticals, and ViaCyte, according to CRSPR Therapeutics. CRISPR Therapeutics' headquarters is in Zug, Switzerland, with its U.S. subsidiary and R&D operations based in Cambridge, MA.


Copyright © 2021 scienceboard.net
 

Create an Account

Already have an account? Sign in Here

To access all ScienceBoard content create a free account now:



Email Address:  

First Name:

Last Name:

Learn about ScienceBoard

Get the latest life sciences research and industry news, delivered straight to your inbox, for free.

Why subscribe?

ScienceBoard is uniquely focused on the business of research, addressing the biggest problems that the biomedical industry face. You’ll get breaking news, events coverage, and deep dives into the science that drives innovation, delivered to your inbox daily.

 
I have read and agree to the privacy policy and terms of service and wish to opt-in for ScienceBoard.net.

Email Preferences



Letter from the Editor Please send me twice-weekly roundups of all the latest life research and industry news.
SAB Announcements Please send me the latest announcements from The Science Advisory Board and their partners.
Spotlight Receive notifications about new content, services, or educational resources designed to help you sharpen your skills and grow professionally.